Mercator Medical SA

Mercator Medical maintains a strong liquidity position with a current ratio of 8.68 and $187.5 million in cash and equivalents, significantly exceeding the industry median for liquidity coverage. The company's debt-to-equity ratio of 0.01 indicates minimal leverage, with long-term debt of only $5.1 million against total equity of $847.4 million. This capital structure provides financial flexibility without exposing the company to significant refinancing risk.

Profitability metrics show mixed performance. The company reported a net income of $11.2 million on $130.9 million in revenue, translating to a 8.6% net margin. However, operating income was negative at -$9.8 million, indicating operational challenges that reduced gross profit of $8.7 million to a net gain. Return on equity of 1.32% and return on assets of 1.19% both fall below the industry median for capital efficiency.

Geographically, Mercator Medical's revenue concentration is not disclosed in the available data, but the company's operations are primarily based in Europe. The business is exposed to regional healthcare policy shifts and supply chain dynamics affecting medical equipment distribution.

Growth trajectory analysis shows a need for improvement. The company's operating cash flow of $1.1 million and free cash flow of $12.2 million indicate limited capacity for reinvestment. Capital expenditures of -$4.2 million suggest asset disposals or underinvestment in growth infrastructure. With no disclosed revenue growth rates in the provided data, the company appears to be operating in a stable but non-expanding revenue environment.

Risk assessment reveals low liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, and shares outstanding remain unchanged between basic and diluted shares. However, the negative operating income raises concerns about operational sustainability without strategic improvements.

Recent filings and transcripts are not available in the provided data, but the company's 10-K Risk Factors would typically address supply chain vulnerabilities and regulatory compliance in the medical equipment sector.

The company maintains a very low debt-to-equity ratio of 0.01, well above the 75th percentile of peers.

Revenue grew 5.8% year-over-year in the latest period, indicating top-line expansion despite profitability challenges.

Dilution and liquidity risks are assessed as low, suggesting stable capital structure and market access.

Capex intensity is lower than the cohort median, implying efficient capital deployment relative to revenue.

The company faces high credit risk, potentially increasing borrowing costs and limiting financial flexibility.

Cash conversion ratio sits in the bottom quartile of peers, indicating poor cash generation from operations.

Revenue PLN 469.1M, −13,5% YoY; Operating income +51,9% YoY.

• ▍Revenue PLN 469.1M, −13,5% YoY
• ▍Operating income +51,9% YoY
• ▍Net income +89,6% YoY
• ▍Free cash flow +76,8% YoY
• ▍Net margin -4.2%

Revenue PLN 542.5M, −68,6% YoY; Operating income −139,1% YoY.

• ▍Revenue PLN 542.5M, −68,6% YoY
• ▍Operating income −139,1% YoY
• ▍Net income −142,4% YoY
• ▍Free cash flow −195,6% YoY
• ▍Net margin -35.0%

Revenue PLN 1.73B; Operating income PLN 463.4M.

• ▍Revenue PLN 1.73B
• ▍Operating income PLN 463.4M
• ▍Net margin 25.9%